bmi for tirzepatide Efficacy and Safety of in Adults with Obesity or Overweight Published July 21, 2022 N Engl J Med 2022;387:205–216 🔹 Background Obesity and overweight remain major global health problems associated with Mounjaro (Tirzepatide) for Medical Weight

The STEP 1 trial, which tested semaglutide 2.4mg in adults with obesity, found that approximately 39% of weight lost was lean mass after 68 weeks

Constipation or diarrhea: Digestive changes occur in some patients, though less commonly than with GLP-1 medications

Depending on the infusion rate and total bag volume, the treatment usually takes between 30-90 minutes and usually involves minimal pain

Indeed, a phase II dose-finding trial demonstrated greater body weight reductions associated with daily subcutaneous semaglutide at a dose greater than 0.2 mg compared with liraglutide 3.0 mg daily [35]

At Ageless Expressions, we believe in a personalized approach to medical weight loss that leads to success

8.Do I need to rotate injection sites